Century Therapeutics Inc. (IPSC)
NASDAQ: IPSCHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IPSC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $211.56M
- EPS (TTM)
- -$0.64
- Dividend yield
- None
- 52-week range
- 0.48 – 3.04
- Day range
- 1.16 – 1.32
- Volume / Avg
- 916.11K / 759.69K
- Beta
- —
- Shares outstanding
- 181.60M
52-week range
IPSC stock today
Century Therapeutics (IPSC) closed at $1.17 on Nov 20, down 11.74% (-$0.155), versus the S&P 500's 3.70% decline. Shares are 61.7% below their 52-week high of $3.04, set on Mar 10, 2026 and 142.7% above the 52-week low of $0.48, in the middle of the past year's range. IPSC is up 17.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 137.8%.
Century Therapeutics has posted a net loss over the last twelve months (EPS of -$0.64), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Century Therapeutics
Company profileCentury Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Brent Pfeiffenberger M.B.A., Pharm.D.
- Headquarters
- Philadelphia, PA
- Employees
- 78
- IPO year
- 2021
- Website
- centurytx.com
Financial highlights
Full financialsIn fiscal 2025, Century Therapeutics generated $109.2 million in revenue, up 1556.8% from fiscal 2024, its 2nd consecutive year of revenue growth. Century Therapeutics reported a net loss of $9.6 million, compared with a loss of $126.6 million a year earlier. Operating margin was -15.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $109.16M | $6.59M | $2.23M | $5.20M | — |
| Growth | +1556.76% | +194.81% | -57.01% | — | — |
| Net income | $-9.58M | $-126.57M | $-136.67M | $-130.93M | $-95.82M |
| EPS (diluted) | $-0.14 | $-1.61 | $-2.30 | $-2.96 | $-2.96 |
Analyst forecast
ForecastConsensus (5 analysts)
buy
Avg. price target
$4.75+307.73%
- Strong buy 1
- Buy 3
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.11 vs $-0.12
- Surprise
- +8.33%
IPSC news
All IPSC news- Century Therapeutics Reports Third Quarter 2026 Financial ResultsNasdaqIPSC, HEI.A
- Century Therapeutics, Inc. Q3 Loss DeclinesNasdaqIPSC, BF.A
- Century Therapeutics Reports Third Quarter 2026 Financial Results and Business UpdatesGlobeNewswire
- Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in LondonGlobeNewswire
Century Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ALLOAllogene Therapeutics Inc. | 0.6277 | -5.88% | $217.48M | vs IPSC |
| CABACabaletta Bio Inc. | 0.9361 | -7.32% | $201.94M | vs IPSC |
| LCTXLineage Cell Therapeutics Inc. | 0.7719 | -5.87% | $195.26M | vs IPSC |
| SCTXScribe Therapeutics Inc. | 12.07 | -8.70% | $228.58M | vs IPSC |
| ARTVArtiva Biotherapeutics Inc. | 3.78 | -1.31% | $186.85M | vs IPSC |
| IKTInhibikase Therapeutics Inc. | 1.32 | +1.54% | $185.16M | vs IPSC |
| AUTLAutolus Therapeutics plc ADR | 0.9073 | -7.38% | $241.65M | vs IPSC |
| PLXProtalix BioTherapeutics Inc. (DE) | 2.90 | -5.23% | $244.52M | vs IPSC |
Indexes, lists and sector
Century Therapeutics stock FAQ
What is Century Therapeutics's stock price today?
IPSC last traded at $1.17 as of Nov 20, 4:00 PM EST, down 11.74% on the day. Prices are delayed at least 15 minutes.
Who is Century Therapeutics's CEO?
Dr. Brent Pfeiffenberger M.B.A., Pharm.D. is the chief executive officer of Century Therapeutics Inc., which has about 78 employees.
What is the IPSC 52-week high?
The 52-week high for IPSC is $3.04 and the 52-week low is $0.48. The stock is currently 61.7% below its high.